

REVIEW ARTICLE

Telomere in Aging and Age-related Diseases

Anna Meiliana^{1,2,*}, Nurrani Mustika Dewi^{1,2}, Andi Wijaya^{1,2}¹Postgraduate Program in Clinical Pharmacy, Padjadjaran University, Jl. Eijkman No.38, Bandung, Indonesia²Prodia Clinical Laboratory, Jl. Cisangkuy No.2, Bandung, Indonesia

*Corresponding author. E-mail: anna.meiliana@prodia.co.id

Received date: Aug 18, 2017; Revised date: Nov 21, 2017; Accepted date: Nov 24, 2017

Abstract

BACKGROUND: The number of elderly population in the world keep increasing. In their advanced ages, many elderly face years of disability because of multiple chronic diseases, frailty, making them lost their independence. Consequently, this could have impacts on social and economic stability. A huge challenge has been sent for biomedical researchers to compress or at least eliminate this period of disability and increase the health span.

CONTENT: Over the past decades, many studies of telomere biology have demonstrated that telomeres and telomere-associated proteins are implicated in human diseases. Accelerated telomere erosion was clearly correlated with a pack of metabolic and inflammatory diseases. Critically short telomeres or the unprotected end, are likely to form telomeric fusion, generating genomic

instability, the cornerstone for carcinogenesis. Enlightening how telomeres involved in the mechanisms underlying the diseases' pathogenesis was expected to uncover new molecular targets for any important diagnosis or therapeutic implications.

SUMMARY: Telomere shortening was foreseen as an important mechanism to suppress tumor by limiting cellular proliferative capacity by regulating senescence check point activation. Many human diseases and carcinogenesis are causally related to defective telomeres, asserting the importance of telomeres sustainment. Thus, telomere length assessment might serve as an important tool for clinical prognostic, diagnostic, monitoring and management.

KEYWORDS: telomerase, cellular senescence, aging, cancer

Indones Biomed J. 2017; 9(3): 113-28

Introduction

Genomic instability was carried along as the cornerstone in cancer development, by accelerating pile of genetic mutation that responsible for cancer cell evolution.(1,2) Genomic instability can occur through a variety of mechanisms, including a defective response to DNA damage, a defect in DNA replication, or a defect in chromosome segregation. The importance of some of these mechanisms has been demonstrated through the study of human genetic diseases that demonstrate both increased chromosome instability and cancer.(3,4)

In every cell cycle, there is always a probability of mistaken for damaged or broken DNA on the ends of eukaryotic chromosomes. This will cause cell permanently arrest in damage cellular pathways. Any attempts to repair would address risks for genome integrity. Telomeres, a protein-DNA complex, work out this problem and prevent the chromosome end from initiating a DNA damage response.(5) Telomeres are composed of repeated DNA sequences bound by a series of specialized protein. It can be ideated as the chromosomes protective cap.(6) Any defect in this cap structure could lead to cell cycle arrest or DNA repair activities which promote an end-to-end fusion of chromosomes via non-homologous

end joining (NHEJ).(7) Telomeres are directly affected by the inability of DNA polymerase to completely replicate the 5' end of a linear chromosome, a situation which known as the end replication problem.(8,9) In each replication, the chromosome terminus loss some DNA and commonly human somatic cells don't have enough capability to compensate. Thus, progressive rounds of replication lead to gradual telomere shortening, until telomeres become critically short and considered as DNA damage.(10) Sensed as damage, a signal will be sent to stop the cell for further divisions and head to senescent pathways. This ability to limit damaged cell proliferation might be one of tumor suppressor mechanism.(11,12)

Contrary, telomere shortening correlates with cellular aging. Therefore, either abnormal telomere shortening or elongation, could detrimental for human health. Extreme telomere shortening due to telomerase deficiency in highly proliferative tissue, for example, can lead to diseases such as dyskeratosis congenita (DKC) or pulmonary fibrosis. (12-15) Conversely, telomerase upregulation leads to the cellular immortalization that is fundamental to cancer cell growth.(16) Telomerase reverse transcriptase (TERT) known to has an essential role in telomere maintenance and in cancer biology.(17) The majority cancer cells depend on the activation of telomerase to gain proliferative immortality. Stem and progenitor cells also express low levels of telomerase.(18) This showed the essential of telomere length regulation for both cellular and organismal well being. Telomere length regulation affect by the structure and composition of the telomere, the availability of telomerase and the interplay between telomere proteins, telomerase and the DNA replication machinery.(19)

Telomeres and Telomerase Biology

Recent comprehensive insight about the mechanisms of age-related diseases, concluded the importance of overall telomere attrition in predicting mortality and those diseases.(20) Telomere roles as a cap to protect the genomic DNA through various mechanisms. One of it is by preventing the recognition of the linear chromosomal DNA end as a broken end, because once it was recognize as a broken end, automatically DNA end-joining, DNA recombination, or DNA repair mechanisms will be processed, leading to unstable chromosomes. Unfortunately, common chromosomal DNA replication machinery cannot completely copy the DNA until the extreme ends of the linear chromosomes, this leads to attrition of chromosome ends after many course of cell divisions.(20)

The structure and function of mammalian telomeres are highly conserved, built on long tandem arrays of duplex TTAGGG repeats ends in a 50- to 400-nt 30 protrusion of the G- rich strand, forming the binding sites for the abundant telomere-specific protein complex, called shelterin (Figure 1). The presence of duplex telomeric repeats, a telomere-specific protein complex, and a 30 protrusion are general themes for all eukaryotic telomeres but the nature of the repeats and proteins vary widely.(21)




Figure 1. Telomere Structure.(20) (Adapted with permission from The American Association for the Advancement of Science).

Based on recent understanding of the molecular pathways that recognize and repair double-strand breaks in mammalian cells, the end-protection problem can be recast in more precise terms (Figure 2).

There are two independent signaling pathways in mammalian cells that are activated by double-strand breaks. First is the ataxia telangiectasia mutated (ATM) kinase pathway, directly activated directly by DNA ends, and then the ataxia telangiectasia and Rad3-related (ATR) kinase pathway, activated by the single-stranded DNA formed when the 5' end of a double-strand break gets trimmed back, or resected.(5)

To avoid premature cellular senescence and the acceleration age-related diseases, the telomere must have ample reserve length, but also telomere shortening is needed to suppress tumor formation. Then, telomere length homeostasis should be achieved.(22) Mammalian telomeres solve the end-protection problem through the agency of a six-subunit protein complex called shelterin.(23) Shelterin is enriched with specificity for telomeres, through the binding complex of several DNA protein to several DNA sequence.




Figure 2. The end-protection problem.(5)
(Adapted with permission from The American Association for the Advancement of Science).

Two shelterin subunits, telomeric repeat factor (TRF)1 and TRF2, bind to the TTAGGG sequences in double-stranded DNA, and one subunit, protection of telomeres protein (POT)1, binds to these sequences in single-stranded form. These three proteins are held together by TRF1-interacting nuclear protein (TIN)2 and tripeptidyl peptidase 1 (TPP1), making the selectivity of shelterin for telomeric DNA is admirable.(5) Meanwhile repressor/activator protein 1 (Rap1) is a stabilizing protein associated with TRF2. Recent studies found that shelterin is not just a static structural component, but it was emerging as a telomere protecting protein complex which have a DNA remodeling activity to change the structure of the telomeric DNA, acts together with several associated DNA repair factors.(23,24) The six subunits of Shelterin on telomeric DNA are shown in Figure 3.

Telomere shortening can also be caused by include nuclease action, chemical (such as oxidative) damage, and DNA replication stress. Telomerase, as well as recombination between telomeric repeats, can counteract these damage-

causing process to restore telomere length.(25) Telomere length is balanced on an equilibrium set point. It shorten during replication and lengthened by telomerase. Any imbalance of this equilibrium leads to disease.(26) Telomerase is an RNA-containing reverse transcriptase that adds telomeric repeat DNA to chromosome ends. (27) This prevent telomeres to be shortened in the end replication problem, which is the failure of the DNA replication machinery to duplicate the very end of each chromosome.(28) As stated before, once telomeres shrink to a critical length, signal will be sent for the cell senescent, or alternatively undergo programmed cell death. This is the major tumor-suppressive mechanism, to prevent any replication of damaged DNA. Continuously dividing cells such as germ cells, stem cells, and, importantly, most cancer cells then require telomerase activity for survival.(29,30)

Telomerase functions as a ribonucleoprotein enzyme. An integral telomerase RNA (TR) component was required, in addition to the catalytic TERT. Extensive studies have identified some structural and functional features within the TR and TERT essential for activity.(31) In eucaryotes, telomerase catalyzes the extension of telomeric DNA. Human telomerase complex involving Cajal bodies in its intracellular trafficking and its recruitment to telomeres. Once recruited, a separate step activated including increase in its repeat addition processivity.(32)

Telomerase is unique among reverse transcriptase (RT) by functioning as a ribonucleoprotein.(33-35) Telomerase's catalytic core is minimally built of the TERT and the integral TR. TERT protein consists of the catalytic site for DNA synthesis, and assembles with the TR to provides the template (Figure 4). When telomerase activity was not needed, many accessory proteins in the holoenzyme take part in crucial roles for telomerase biogenesis, localization, and regulation.(36-40)




Figure 3. The six known subunits of Shelterin on telomeric DNA.(24) (Adapted with permission from PubMed Central).




Figure 4. Telomere Structure.(40) (Adapted with permission from John Wiley & Sons, Inc). TERC: telomerase RNA component; NHP2: non-histone protein 2; NOP10: nucleolar protein 10; GAR1: glycine arginine rich.

TERTs usually consist of four domains: the telomerase essential N-terminal (TEN) domain, the telomerase RNA-binding domain (TRBD), the RT domain, and the C-terminal extension (CTE). The TEN domain interacts with telomerase reverse (TER) and traps single-stranded telomeric DNA to promote processive repeat synthesis.(41-43) This processes undergo by capturing the substrate and maintain the association with those single-stranded products.(44) The TRBD confers the specificity of interaction between TERT and TER.(41,45) Motifs preserved in the evolutionarily related retrotransposon RTs forms the active site in RT domain. Here, aspartic acid residues coordinate the magnesium ions needed for catalysis of deoxynucleotide (dNTP) addition.(46) In TERTs, this domain also positions the template and aligns the substrate 3' end.(47,48) RT domain function could be enhanced by the CTE and/or the nucleic acids.(49,50) So far, mutations in at least six telomerase components have been linked to human telomere-mediated disorders such as DKC, aplastic anemia (AA), and idiopathic pulmonary fibrosis (IPF).(16,17,51) Most cancer cells have their telomerase up-regulated so then they keep growing.(52)

Telomerases important role in oncogenesis is highlight due to recurrent mutations recently identified in the promoter of the gene for the hTERT (human TERT) telomerase protein component (53,54), the most frequent mutation in some cancer types (55). These promoter mutations are associated with increased hTERT expression, telomerase activity, and telomere length.(56) Otherwise, telomerase activity, its maturation, or the recruitment to telomeres deficiencies lead to human diseases such as aplastic anemia and DKC.(57)

Cellular Senescence

All the time our cells experience stress and damage continuously either exogenous or endogenously. The responses range from complete recovery to cell death. Proliferating cells can commence a further response by adopting a state of permanently cell growth arrest, termed cellular senescence.(58,59)

Cellular senescence was first defined by Hayflick as the ultimate and irreversible loss of replicative capacity occurring in primary somatic cell culture.(60) His study found that cell growth was reproducibly blocked after a fairly well-defined number (under constant culture conditions) of population doublings (PD), and this suggested the idea of a biological clock or, more specifically, a replication counter (61) that counts biological time in numbers of cell divisions, and after a reproducible number of divisions triggers signaling pathways that block cellular division. Several different processes have been suggested as possible clocking mechanisms (62), but telomere uncapping (63) is by far the best established and most extensively investigated of these besides the epigenetic derepression of the INK4a/ARF locus, and DNA damage.(58) Cellular senescence protects against the development of cancer, while it also may be involved in aging.(59,64) The consequences of cellular senescence is the radically phenotype altering which thought to impair tissue function and predispose tissues. Accumulation of these known as “replicative senescence” will progress to diseases.(65,66) Oxidative stress and activated oncogenes such as Ras have also been shown to trigger cellular senescence.(67,68).

Degree of telomere shortening is quickened by oxidative damage, then telomere shortening could reflect the accumulation of oxidative damage.(69) Aging was known to be correlated with oxidative accumulation and the gradual of senescent cells accumulation induce aging mechanism of mitotic tissues. Senescent display a radically altered phenotype, genetic, morphology, and behavior clearly from its growth-competent counterparts. Supposed that the neighbor cells, extracellular matrix and other structural components affecting the process of aged tissues, increased the risk of cancer.(70-73) Together with senescent cells accumulation, senescence also limiting the regenerative potential of stem cells pools or loss of stem cell function. These two combination probably contribute to simultaneously aging process (Figure 5).(59)

Senescence was mediated by cell's two main tumor suppressor pathways, the ARF/p53 and the INK4a/RB




Figure 5. Short telomeres activate a DNA-damage response that leads to apoptosis and senescence.(15) (Adapted with permission from Annual Reviews)

pathway.(74,75) Ectopic expression of oncogenic Ras in primary cells demonstrated a senescent-like arrest mediated by p53 and p16^{INK4a}, proved that oncogene-induced senescence could be a mechanism of potentially dangerous cells growth retrain.(76) Thus, deprivation of these tumor suppressors mechanisms essentially achieve the oncogenic transformation of human cells in vitro (77), and indeed these pathways are frequently disrupted in human cancer cells (74,75).

The senescence growth arrest is not simply a halt to cell proliferation, akin to the reversible growth arrest of quiescence. Rather, senescent cells distinct from quiescence or terminal differentiation.(78) Among the prominent senescence-associated changes in gene expression, numerous cytokines, chemokines, growth factors and proteases of expression and secretion vigorously increased (79-84). This termed as the senescence-associated secretory phenotype (SASP).(85) SASP of senescent cells can cause normal cells to lose their optimal function, leading to tissue degeneration, and cause premalignant cells to proliferate and adopt more malignant phenotypes, promote to full-blown cancer.(85)

Senescence beta-galactosidase (SA- β -GAL) is a frequently used senescence biomarker.(86,87) Encoded by galactosidase beta-1 (GLB1) gene from lysosomal β -D-galactosidase, SA- β -GAL activity increased in senescent cells. The enzymatic activity of SA- β -GAL has to be preserved for detection, so the tissues should be snap-frozen (87). Also, non-senescent cells display β -galactosidase

activity in the lysosomes that functions most optimally at pH 4.(88) Therefore, senescent cells underwent a lysosomal compartment expansion, giving rise to an increase in β -galactosidase activity and can be measured at suboptimal pH 6 (hence, SA- β -GAL).(88-91)

Deeper understanding of the senescent phenotype of all mitotic cell-type will provide better assess for the potential consequences of their appearance, therefore we can combat the problem into three strategies: 1) prevention, 2) removal and 3) replacement.(65)

Telomere and Aging

Aging can be defined as the progressive functional decline of tissue function yet results in mortality. The weakening can result from diminished or loss function of post-mitotic cells or due to functional decline in stem cell ability to replace cells, sustain replications and cell divisions. Aging should not be understood as disease but a context of evolution, such as The Disposable Soma model, proposed by Thomas Kirkwood in 1977, presumes that our body must budget the amount of energy available to it, and the compromise in energy allocation to the repair function will cause the body gradually to deteriorate with age.(92)

As the world population ages, it has become increasingly important to understand the physiologic consequences of aging and quickly identify those changes that are likely to result in progression to frailty. Frailty, to distinguish it from normal aging, usually implies a state of heightened vulnerability to acute and chronic stressors as consequences of significant reduction in physiologic reserve. It is usually associated with decline in function across multiple systems that in composite contribute to geriatric syndromes, including falls, osteoporotic fractures, incontinence, cognitive decline, anemia, malnutrition, and muscle wasting.(93)

Aging manifest in overall decline in various organs function capacity in maintaining baseline tissue homeostasis and adequate physiological responses under stress (94,95). This process usually gradual, means modest in middle years aged tissues but late in life will accelerate rapidly and likely put organism into serious challenge of regenerative response. At the anatomical and physiological levels, deficient regenerative response and decreased tissue cellularity seems to be closely related to many of classic age medical syndrome, such as muscle atrophy, anemia, feeble immune responses and impaired wound healing.(96)

In term of cell fate and aging, telomeres play important roles by accustom the cellular response to stress and growth stimulation due to any DNA damage and previous cell divisions. To desist from DNA repair pathway activation, hundreds of nucleotides of telomere repeats must cap each chromosome end. Critically short or uncapped telomeres will be repaired by telomerase or recombination, but it was limited in most somatic cells. When too many uncapped telomeres accumulated, then cellular senescence is triggered. Germline cells usually express high levels of telomerase, so the telomere length is maintained. In somatic cells, the length is high diverse but commonly decline with age, as a barrier to tumor growth but as results the cells lose with age.(97)

Throughout a life time, our body supposed to possess a notable ability for continuous extensive and sustained tissue renewal, due to reservoirs of somatic tissue stem cells (98,99), but aging and regenerative researches show parallels blunted proliferative responses and misdirected differentiation of resident tissue stem cells parallel with age. In the other side, these long-lived renewable reservoirs can also affect the health of aged individuals negatively by providing a preferred cellular compartment for malignancy.(99)

Many human studies in genetic disorders has confirmed the relevancy of DNA damage signaling and metabolic regulation to drive the ageing process. Specifically, functional decline of tissue stem cells can primarily instigated with age-associated telomere damage, alleviation of telomere capping function and associated p53 activation. Together with mitochondrial dysfunction, these will affect in tissues renewal and bioenergetic support. A hypothetical model connecting telomere damage, p53 activation, stem cell, and mitochondrial dysfunction offers a unifying explanation about how telomeres impact aging organism.(96)

The genotoxic stress model of aging, the core telomere-p53 axis integrates well with almost all genetic elements proven to be important in the aging process. First, it accounts for the premature aging phenotypes common to both telomere-dysfunctional mice and those with germline p53 hyperactivation.(100,101) Second, it describes how premature aging happened in mice lacking of SIRT1 or SIRT6, proteins that disable p53 activity.(102) Third, it explains the link between mitochondria and key aging factors: Peroxisome proliferator-activated receptor gamma coactivator (PGC)-1 α , PGC-1 β , forkhead box O (FOXO) proteins and B lymphoma Mo-MLV insertion region 1 (BMI1); mice with lack of these genes experience

accelerated tissue degeneration and mitochondrial dysfunction.(96)

Revealing these networks by constructing a model of interaction between telomeres, stem cells and mitochondria will provide us advance biomarkers for aging and the strategies for therapy, *i.e.*, telomeres stabilization either through brief telomerase reactivation, p53 modulation, mitochondrial function and biogenesis improvement, and mechanistic target of rapamycin (mTOR) and phosphoinositide 3-kinase (PI3K) pathways modulation, to rejuvenate both proliferating and quiescent the aged tissues.(96)

Telomeres and Cancer

Today, withdrawal from the cell cycle after a certain number of cellular divisions (replicative senescence) is known to be triggered by shortened telomeres(103) Recent studies made us learned that cancer cells have evolved their ability to overcome senescence (52,104) because they can maintain the telomere lengths (such as expressing telomerase), then cancer cells are capable to divide indefinitely (104), a biomarker of almost all advanced human cancers.(30)

To limit tumors' clonal proliferation, dominance and ensures a polyclonal composition of (stem) cells in large, long-lived multicellular organisms, human somatic (stem) cells loss its telomeric DNA progressively. Regrettably, this induce somatic cells to ignore or bypass the telomere"checkpoint (105), *e.g.*, because their DNA damage responses are defective. Loss of telomere function like this can results in chromosome fusions, broken chromosomes, break-fusion bridge cycles, translocations, and aneuploidy, creating a genetic instability that grows further genetic alterations rapidly.(106,107) This way, telomere loss could also promote tumor growth by driving selection of cells with defective DNA damage responses (*e.g.*, loss of p53).(29,108) DNA damage responses involving normal and dysfunctional telomeres with intracellular signaling pathways, while DNA repair involving proteins such as ATM, ATR, and p53.(109) Together these demonstrate telomeres as determinant dynamic elements required for genome stability, regulating the cell response under stress and growth stimulation.(97)

Crisis is a period where cell growth and death are in balance. In chromosome end fusions, chromosome breakage-fusion-bridge (BFB) happened leads to genomic instability, chromosome rearrangements, and eventually telomerase engagement. However, telomerase encountered

in approximately 90% of all malignant tumors (52), may predict poor or favorable outcome (110,111), thus making telomerase both a highly attractive biomarker and target for the development of mechanism-based cancer diagnostics, prognostics, and therapeutics.(30)

Genome instability caused by telomere crisis was found to induce chromosome gains and losses (aneuploidy), translocations, gene loss (manifested as loss of heterozygosity (LOH)) and regional amplification through BFB cycles (Figure 6).(108,112,113) The genomic alterations included whole genome reduplication, chromothripsis and kataegis.(114-116) Telomere fusions can occur between different chromosomes or between sister chromatids after DNA replication, thus leading to different outcomes.(4) BFB cycles generally can lead to three outcomes related to cancer: LOH, nonreciprocal translocations and gene amplification. LOH frequently found in cancer-relevant loci, could arise if when a dicentric chromosome breaks and one of the daughter cells inherits a chromosome with a terminal deletion. Nonreciprocal translocations could arise when the DNA end of a broken chromosome invades another chromosome and copies part of this chromosome through a process called break-induced replication.(117,118) Nonreciprocal translocations occur during tumorigenesis in mice with shortening telomeres and are a frequent class of rearrangements in cancer.(119) Sequence analysis of more than 1,000 telomere fusion events has shown that a chromosome end lacking telomere protection can recombine with diverse chromosome internal loci (120).

Malignant tumors collectively characterized by telomerase expression, to service the unlimited cell proliferation, otherwise most benign and premalignant tumor characterized by the absence of telomerase.(121) Somatic mutations in the proximal promoter of the human TERT now become the most familiar noncoding mutation in cancer.(122)

Therefrom, telomerase become a very attractive target for any immortal cells including cancer stem cells. Telomerase expression, telomere length and cell kinetics between normal and tumor tissues are very different, thus make it more delicate for telomerase to be a relative safe target for many developing therapy such as vaccines, and specific telomerase inhibitor, imetelstat sodium (GRN163L).(123) The key advantages of targeting telomerase in comparison with most other cancer targets are its relative universality, criticality and specificity for cancer cells, including the putative cancer stem cell. Telomerase is expressed in the majority of tumours from all cancer types




Figure 6. BFB cycles and chromosomal rearrangements during telomere crisis.(110) (Adapted with permission from Nature Publishing Group).

(52,121,124) and some recent studies have suggested that cancer stem or stem-like cells are also telomerase-positive (125-128).

Telomeres and Diseases

Recent findings suggests, as the most risk factors for chronic disease, aging is the feasible modifiable one.(129) not only the apparent signs such as gray hair, wrinkle and spotting skin, muscle wasting, altered adiposity, but aging increase the susceptibility to diseases as people enter the last decades of life, including sufficient immune function, cardiovascular diseases (CVD), cancers, type 2 diabetes mellitus (T2DM), depression, and especially cognitive decline, although they are also could happened as comorbid disease in younger people.(20) Both aging and disease result in the same outcome: the impairment of normal biological function. It would not, therefore, be a surprise if tissue dysfunction resulting from an aging mechanism eventually manifested itself as a disease. Therefore, we expect new development

in prevention and therapeutic methods by understanding the process of aging.(65)

Cellular senescence, as one basic process that play most contribution to age-related dysfunction and chronic sterile inflammation, refers to the essentially irreversible growth arrest that occurs when cells experience potentially oncogenic insults (58,130-134), and now believe that it was the potent anticancer mechanism (135-138). In contrast, despite its name, its discovery over 50 years ago, and increasing data associating senescent cells with aging phenotypes and age-related pathology (59,139-145), while eliminating senescent cells could delay age-related dysfunction (146), at least in a progeroid mouse model.

Cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) are clearly related to age and can reduced life span.(147) in fact, people with same age do not experience the same cardiometabolic outcome, suggest that chronological age is not a precise measure for health status.(148) and we need a better biomarker to identify the cardiometabolic health so we not only can predict but also prevent the disease. Leukocyte telomere length (LTL) may be one such biomarker.(149)

Normally, LTL is reduced in normal aging with considerable inter-individual variation, supposed this reflects the biological age of the cells and organism, which could be different with chronological age (59,150), influenced by own genetic factors, lifestyle and disease. As example, regular exercise slow leukocyte telomere erosion (151,152), while obesity is associated with reductions in LTL (153,154). Current studies reported an association between LTL and chronic diseases including CVD and T2DM (154,155). As we know that those chronic disease, arthritis, together with aging normally involve increased oxidative stress and inflammation. Reduced LTL suggested to be responsible for those stressors.(156)

The 5'-TTAGGG-3' repeats in the telomere sequence are prone to oxidative damage (8-oxodG). ROS-induced DNA breaks, so oxidative stress could promote telomere shortening in leukocytes and other cells in parallel with aging and chronic disease state.(157,158) Markers of oxidative stress are also elevated in association with shorter LTL in patients with rheumatoid arthritis (159) and T2DM (160). DNA damage in telomeres is very stable and not easily repaired, that's why telomere shortening caused by reactive oxygen species (ROS) will be accelerated.(161) In addition to oxidative DNA damage, impaired calcium homeostasis in Alzheimer disease (AD) patient lymphocytes can also induce telomere erosion.(162,163) Oxidative stress can release calcium from mitochondria then triggers a viscous

cycle of telomere shortening, promote more mitochondrial dysfunction that elevating ROS and leads to DNA damage which worsen the telomere shortening.

LTL associated with increasing stress hormones level such as norepinephrine, epinephrine, cortisol and insulin-like growth factor (IGF)-1.(164-166) Exaggerated activation of HPA cause decreased of growth hormone (GH) and affecting the telomere maintenance.(167) Stress responses also affect in decreased dehydroepiandrosterone (DHEA) and increased bulk lymphocyte proliferation and markers of oxidative damage, in total resulting in stress-induced leukocyte telomere erosion.(156,165)

Although not immediately, telomere shortening in leukocytes and microglia can affect neuronal health by compromising the normal functions of these immune cells within the brain.(168,169) The roles of the immune system in the initiation and progression of Newcastle disease (ND) are being actively investigated.(170) Telomere shortening in immune cells, astrocytes and neurons could amplify oxidative stress-dependent senescence and secretion of pro-inflammatory mediators (senescence-associated secretory phenotype), results in diseases progression.(59,168,171). The shortest telomere within a cell showed to pronounce cell senescence the most as well (172,173).

Chronic psychologic stress has been associated with shorter telomeres during childhood and adulthood, although not consistently. Children and adults with adverse and disadvantaged early life experiences (174-178), women who provide care for a family member with a chronic health condition (179-181), those who report high perceived stress (180-182) and women exposed to domestic violence (183) have shorter telomeres in leukocytes and varying subtypes of immune cells compared with those who have not experienced such stressors. Severity and chronicity of depression are also related to shorter telomeres.(184-186) Women with high consistency of healthy behavior appeared to be more protected although exposed to same level of stress, showed that telomere length can be expected to be maintained.(187)

Telomeropathies, a disorder caused by defects in the telomere maintenance machinery, just recently discovered shared a constellation of overlapping syndromes.(188,189) DKC was the first disorder associated to telomeropathy, manifest the diagnostic triad of oral leukoplakia, skin hyperpigmentation, nail dystrophy (190-192), most prominent display organ failure, usually in the bone marrow and a seri of symptoms that less frequently appear such as aplastic anemia or specific lymphopenias. (193,194)

In adulthood, idiopathic pulmonary fibrosis (IPF) is the most common symptom of a telomeropathy.(57) IPF is characterized by progressive failure of the lung coincident with fibrosis and inflammation.(195) Around 8-20% of familial cases of IPF were in responsible of TERC and TERT inherited mutation (196), while 37% of familial cases and 25% of sporadic cases were correlated with shorter telomeres compared to the 10th percentile of the general population, besides as-yet undiscovered genetic or environmental causes (197). Other adult-onset manifestations of impaired telomere maintenance include familial liver cirrhosis (198), aplastic anemia in adulthood (199), and sporadic acute myelogenous leukemia (AML), in which both somatic and germline mutations have been found (200).

Biomarkers of Aging and Diseases

Early 1980s, scientists tried to define aging and its better predicting biomarkers objectively, separate from diseases but not universally accepted while biomarkers for diseases is conceptually more straight forward.(201-203) Valid aging biomarkers, which is describe the rate of aging than chronological age were expected to allow the evaluation of any better prevention and interventions.(204) A simpler set of aging biomarker criteria was proposed by Miller in Butler, *et al.*, are: 1) Biomarkers which cover multiple physiological and behavioral domains, in association with age, so it can predict the outcome of a broad spectrum of age-sensitive tests better than chronological age; 2) It should intertwine biomarkers of aging with biomarkers of disease and suggests that biomarkers of aging will be measuring degenerative changes; 3) The measurement will not alter another age-sensitive tests results or life expectancy of subjects.(205)

The major argument for the development of biomarkers of age-related disease could be summed up as follows: 1) Many age-related diseases develop over long periods and are not observable until they are well established; 2) Successful treatment of disease often requires early diagnosis and treatment; 3) Early biomarkers would permit such treatment when it has a better chance of producing a positive result than treatment begun late in the disease process; and 4) Biomarkers would provide measures to assess the effects of treatment in less than the lifespan of the organism.(204)

Telomeres play quite roles in brain biology and are found shortened in patients with neurodegenerative diseases such as dementia or AD.(206-209) In cellular immunology,

telomerase activators were proven to boost immune system of human and mice (210-212), suggested that was associated with stem cells pools mobilizations by telomerase, particularly in this case, the hematopoietic stem cell niches. Telomere shortening also correlates with cardiovascular diseases. Thus, telomeres as indicators of biological aging and diseases. Many studies proven the association between LTL to stroke, myocardial infarction and T2DM. 1 SD in LTL could significantly raise stroke incident (OR 1.21, CI 1.06–1.37; I²=61%), myocardial infarction (OR 1.24; 95% CI 1.04–1.47; I²=68%), and T2DM (OR, 1.37; 95% CI 1.10–1.72; I²=91%). Shortened leukocyte telomere length demonstrates a significant association with stroke, myocardial infarction, and type 2 diabetes mellitus.(149)

β -galactosidase (β -Gal) expressed only in senescent cells, not in pre-senescent or quiescent fibroblasts or keratinocytes. At pH 6.0 using immunohistochemistry, β -Gal can be used as one of the best, reliable and simple methods to measure senescence *in vitro* and *in vivo*.(86,213-219) SA- β -GAL demonstrated a positive correlation with increasing age using human skin samples.(86) So, SA- β -GAL can be used as a marker for senescence in senescent protocol or through senescence-induced methods involving DNA damage agents, oncogenic signals, or over-expression of tumor suppressors such p16 and ARF.(220)

A crucial marker of senescent cell is senescence-associated heterochromatin foci (SAHF). Employing the concept of irreversibility senescent cells, they present a characteristic heterochromatin condensation structure involving the formation of heterochromatic foci (221) which was visible under microscopy, and defined by condensed regions of DNA/chromatin. SAHF are known to silence and repress several E2F-regulated genes such as MCM3, PCNA, or Cyclin A (221-223) and are known to be triggered by several pathways involving p16 or p53 activation.(223)

Conclusively, the ideal biomarker for senescence are cancer and aging marker, therefore ideally can be used for degenerative diseases and cancer studies *in vivo*.(224) Telomere shortening represents the accumulation of DNA damage and its intrinsic mechanism during cell aging, which finally result in senescent.(10,225) The lifestyle factors (such as exercise, smoking, body mass) influence on the aging associated to the expression of serum markers of DNA damage (Cathelicidin-related antimicrobial peptide (CRAMP), elongation factor (EF)-1 α , Stathmin, n-acetyl-glucosaminidase, and chitinase) in comparison to other described markers of cellular aging (p16^{INK4a} upregulation and telomere shortening) in human peripheral blood. The study showed that lifestyle factors can affect age-

independent level of DNA damage biomarkers. Smoking and increased BMI significantly correlated with increased the level of biomarkers expression, apart from subjects' chronological age. In contrast, exercise was associated with an age-independent reduction in the expression of biomarkers of DNA damage in human blood.(152)

Telomerase As Therapeutic Target

We can now understand the limitation on cell division as a mechanism for tumor suppression. Indeed, in mice, cancer growth was hindered due to shorten telomere. On the other hand, when telomeres become very short it also could provoke tumor growth by genome instability. TERT can preserve the telomere length. The human telomerase consists of two subunits: a RNA templates, TERC, and the catalytic subunit, hTERT, which synthesizes the new telomeric DNA from the RNA template.(226) Cells who need a high replicative capacity, such as stem cells and progenitor cells have a higher activity of telomerase.(227) Telomerase elongates telomere, therefore stabilize chromosomes, and rejuvenate gene expression pattern. The hTERT, out of the established role, could promote proliferation of resting stem cells via a non-canonical pathway (227) and perform a direct effect on cell transcription and signaling, *e.g.*, as a cofactor in a β -catenin transcriptional complex (228), which plays a role in embryogenesis and development (229). Telomerase alone is not an oncogene, but permissive for carcinogenesis, so uncontrolled induction of telomerase would have a pitfall. ~90% tumor cells express more telomerase, makes telomeres as an overlap target for both anticancer and cell rejuvenation at different cellular and functional levels.(230)

Recent knowledges lead more idea to reverse normal cellular aging process to treat aging symptoms. Many studies tried to develop telomerase activators that may induce hTERT and/or hTR expression, enhance enzyme activity and/or influence cellular location, and came up single molecule such as cycloastragenol, derived from *Astragalus membranaceus* root (commercially available as TA-65), proved to transiently activate telomerase in T lymphocytes in the retardation of telomere shortening, increased proliferative potential, and enhanced functional response.(210,231) TA-65 also shown to improve the accelerated immunosenescence in HIV patients and increased the number of senescent memory CD8 T cells. (210,231) Since 2013, TA-65 sold as supplement and give benefit for activating telomerase in immune cells, neonatal keratinocytes, and fibroblasts.(210,232) TA-65 acts via

extracellular-signal-regulated kinase (ERK)-pathway activation and subsequent enhancement of telomerase expression without increasing the cancer incidence (233).

Other phytochemicals have been shown to activate telomerase. Resveratrol activates telomerase in mammary epithelial (234) and endothelial progenitor cells (235), most likely due to the upregulation of sirtuin (SIRT)1 although the long-term effects study is not incomplete yet (236). N-acetylcarnosine has been proposed as telomerase activator for cataracts treatment, because reduced telomere length is known intimately involved in opacification, making the lens opaque or cloudy.(237) Another compound that has proven to have a neuroprotective effects in mice and showed delayed progression of amyotrophic lateral sclerosis and increased survival in SOD1 transgenic mice is AGS-499.(238)

Some antioxidants such as N-acetylcysteine may also have indirect effect to upregulate telomerase activity by blocking the nuclear export of telomerase into the cytosol.(239) The α -tocopherol, shown to retain telomerase activity in brain microvascular endothelial cells.(240) ROS damage telomeres directly through vulnerable GGG triplet of the repetitive telomere sequence, and indirectly via telomerase activity modulating and cellular location.(241) So, hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors could also have telomere lengthening effects (242), by interfering with the redox balance of cells (239) and by increasing expression of the telomere stabilizing protein TRF2 (243). Finally, Ginkgo biloba was shown to activate telomerase by inducing PI3K/Akt signaling.(244)

The successful strategies in activating telomerase and rejuvenate cells applied in many tissue engineering and reconstructive surgery for extending cell lifespan. However this may accumulate genetic and epigenetic aberrations that can contribute to malignant transformation.(230) Several approaches for a telomerase-based gene therapy in the treatment of cancer then be developed, due to higher telomerase activity in cancer cells, compared to most other cells.(52) Accordingly, approaches to block TERT have been pursued. One prominent example is Geron specifically modified oligonucleotide chemistry GRN163L which is complementary to TERC and, thus, able to bind to the catalytic center of TERT thereby inhibiting its function.(245) In contrast to direct TERT blockade, immunotherapeutic approaches use TERT-derived peptides to develop vaccines that would activate the immune system to specifically target cancer cells with high TERT expression. GV1001 is such a peptide vaccine that is currently under investigation in a substantial number of clinical trials.(230)

Some difficulties in using telomerase as cancer therapeutic targets includes: First, anti-proliferative effects of telomerase inhibition only induced in cells with short telomeres so the drug need quite a time to be effective, while the tumor is growing. Second, the inhibition of telomerase cannot yet be specific for certain cells, so any highly proliferative cells which need telomerase for survival, namely, stem cells, etc will regard this treatment negatively.(239) Thus, a narrow telomere length window therapy could be the answer for now.(246)

Conclusion

Telomeres physically could define as the edge of chromosomes, to protect them from nucleolytic degradation and DNA repair activities. Traditionally, lack of enzymes limit the ability of DNA replication to fully replicate telomere ends. Together with nucleolytic activities, telomere will be eroded in each replication, while telomere length homeostasis is essential for cell survival. Shortened telomere generate DNA damage, induce cellular senescence and apoptosis, and cause short telomere syndromes and associated age – related disease. Telomerase act de novo to counterbalance this shortened telomere by adding telomere sequences. On the other hands, elongated telomeres were found in cancer cells. They escape senescence to allow immortal growth. Telomere biology is best viewed in context: It was raising as a powerful inter-active factor for precision medicine in health monitoring and assesing disease, so we need further studies about the genetic and non-genetic determinants interaction in this telomere length maintenance, on different diseases.

References

1. Tlsty TD. Genomic instability and its role in neoplasia. *Curr Top Microbiol Immunol.* 1997; 221: 37-46.
2. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. *Nature.* 1998; 396: 643-9.
3. Taylor AM. Chromosome instability syndromes. *Best Pract Res Clin Haematol.* 2001; 14: 631-44.
4. Murnane JP. Telomeres and chromosome Instability. *DNA Repair.* 2006; 5: 1082-92.
5. de Lange T. How telomere solve the end-protection problem. *Science.* 2009; 326: 948-52.
6. de Lange T, Lundblad V, Blackburn EH. Telomeres. New York: Cold Spring Harbor Laboratory Press; 2006.
7. O'Sullivan RJ, Karlseder J. Telomeres: protecting chromosomes against genome instability. *Nat Rev Mol Cell Biol.* 2010; 11: 171-81.
8. Gilson E, Geli V. How telomeres are replicated. *Nat Rev Mol Cell Biol.* 2007; 8: 825-38.
9. Verdun RE, Karlseder J. Replication and protection of telomeres. *Nature.* 2007; 447: 924-31.
10. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, *et al.* A DNA damage checkpoint response in telomere-initiated senescence. *Nature.* 2003; 426: 194-8.
11. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. *Carcinogenesis.* 2010; 31: 9-18.
12. Lansdorp PM. Telomeres and disease. *EMBO J.* 2009; 28: 2532-40.
13. Armanios M. Syndromes of telomere shortening. *Annu Rev Genomics Hum Genet.* 2009; 10: 45-61.
14. Armanios M. Telomerase and idiopathic pulmonary fibrosis. *Mutat Res.* 2012; 730: 52-8.
15. Nelson ND, Bertuch A. Dyskeratosis congenita as a disease of telomere maintenance. *Mutat Res.* 2012; 730: 43-51.
16. Buseman CM, Wright WE, Shay JW. Is telomerase a viable target in cancer. *Mutat Res.* 2012; 730: 90-7.
17. Sandin S, Rhodes D. Telomerase structure. *Curr Opin Struc Biol.* 2014; 25: 104-10.
18. Gunes C, Rudolph KL. The role of telomeres in stem cells and cancer. *Cell.* 2013; 152: 390-3.
19. Stewart JA, Chaiken MF, Wang F, Price CM. Maintaining the end: roles of telomere proteins in end-protection, telomere replication and length regulation. *Mutat Res.* 2012; 730: 12-9.
20. Blackburn EH, Epel ES, Lin J. Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. *Science.* 2015; 350: 1193-8.
21. Doksan Y, de Lange T. The role of double-strand break repair pathways at functional and dysfunctional telomeres. *Cold Spring Harb Perspect Biol.* 2014; 6: a016576. doi: 10.1101/cshperspect.a016576.
22. Hug N, Lingner J. Telomere length homeostasis. *Chromosoma.* 2006; 115: 413-25.
23. De Lange. Shelterin: the protein complex that shapes and safeguards human telomeres. *Genes Dev.* 2005; 19: 2100-10.
24. De Boer R, van der Harst P, Van Gilst WH. Telomere biology in healthy aging and disease. *Eur J Physiol* 2010; 459: 259-68.
25. Xie Z, Jay KA, Smith DL, Zhang Y, Liu Z, Zheng J, *et al.* Early telomerase inactivation accelerates aging independently of telomere length. *Cell.* 2015; 160: 928-39.
26. Greider CW. Regulating telomere length from the inside out: the replication fork model. *Genes Dev.* 2016; 30: 1483-91.
27. Blackburn EH, Collins K. Telomerase: an RNP enzyme synthesizes DNA. *Cold Spring Harb Perspect Biol.* 2011; 3: a003558. doi: 10.1101/cshperspect.a003558.
28. Levy MZ, Allsopp RC, Futcher AB, Greider CW, Harley CB. Telomere end-replication problem and cell aging. *J Mol Biol.* 1992; 225: 951-60.
29. Stewart SA, Weinberg RA. Telomeres: cancer to human aging. *Annu Rev Cell Dev Biol.* 2006; 22: 531-57.
30. Shay JW, Wright WE. Role of telomeres and telomerase in cancer. *Semin Cancer Biol.* 2011; 21: 349-53.
31. Podlevsky JD, Chen JL. It all comes together at the ends: Telomerase structure, function, and biogenesis. *Mutat Res.* 2012; 730: 3-11.
32. Schmidt JC, Cech TR. Human telomerase: biogenesis, trafficking, recruitment, and activation. *Genes Dev.* 2015; 29: 1095-105.
33. Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. *Nature.* 1989; 337: 331-7.
34. Shippen-Lentz D, Blackburn EH. Functional evidence for an RNA template in telomerase. *Science.* 1990; 247: 546-52.

35. Yu GL, Bradley JD, Attardi LD, Blackburn EH. In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs. *Nature*. 1990; 344: 126-32.
36. Fu D, Collins K. Distinct biogenesis pathways for human telomerase RNA and H/ACA small nucleolar RNAs. *Mol Cell*. 2003; 11: 1361-72.
37. Kiss T, Fayet-Lebaron E, J dy BE, Box H/ACA small ribonucleoproteins. *Mol Cell*. 2010; 37: 597-606.
38. Egan ED, Collins K. Specificity and stoichiometry of subunit interactions in the human telomerase holoenzyme assembled In Vivo. *Mol Cell Biol*. 2010; 30: 2775-86.
39. Venteicher AS, Abreu EB, Meng Z, McCann KE, Terns RM, Veenstra TD, *et al*. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. *Science*. 2009; 323: 644-8.
40. Buckingham EM, Klingelhutz AJ. The role of telomeres in the ageing of human skin. *Exp Dermatol* 2011; 20:297-302.
41. O'Connor CM, Lai CK, Collins K. Two purified domains of telomerase reverse transcriptase reconstitute sequence-specific interactions with RNA. *J Biol Chem*. 2005 280: 17533-9.
42. Jacobs SA, Podell ER, Cech TR. Crystal structure of the essential N-terminal domain of telomerase reverse transcriptase. *Nat Struct Mol Biol*. 2006; 13: 218-25.
43. Robart AR, Collins K. Human telomerase domain interactions capture DNA for TEN domain-dependent processive elongation. *Mol Cell*. 2011; 42: 308-18.
44. Collins K. Single-stranded DNA repeat synthesis by telomerase. *Curr Opin Chem Biol*. 2011; 15: 643-8.
45. Lai CK, Mitchell JR, Collins K. RNA binding domain of telomerase reverse transcriptase. *Mol Cell Biol*. 2001; 21: 990-1000.
46. Belfort M, Curcio MJ, Lue NF. Telomerase and retrotransposons: Reverse transcriptases that shaped genomes. *Proc Natl Acad Sci*. 2011; 108: 20304-10.
47. Xie M, Podlevsky JD, Qi X, Bley CJ, Chen JJ. A novel motif in telomerase reverse transcriptase regulates telomere repeat addition rate and processivity. *Nucleic Acids Res*. 2010; 38: 1982-96.
48. Qi X, Xie M, Brown AF, Bley CJ, Podlevsky JD, Chen JJ. RNA/DNA hybrid binding affinity determines telomerase template-translocation efficiency. *EMBO J*. 2012; 31: 150-61.
49. Autexier C, Lue NF. The structure and function of telomerase reverse transcriptase. *Annu Rev Biochem*. 2006; 75: 493-517.
50. Wyatt HD, West SC, Beattie TL. InTERTpreting telomerase structure and function. *Nucleic Acids Res*. 2010; 38: 5609-22.
51. Kirwan M, Dokal I. Dyskeratosis congenita, stem cells and telomeres. *Biochim Biophys Acta*. 2009; 1792: 371-9.
52. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, *et al*. Specific association of human telomerase activity with immortal cells and cancer. *Science*. 1994; 266: 2011-5.
53. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, *et al*. TERT promoter mutations in familial and sporadic melanoma. *Science*. 2013; 339: 959-61.
54. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. *Science*. 2013; 339: 957-9.
55. Heidenreich B, Rachakonda PS, Hemminki K, Kumar R. TERT promoter mutations in cancer development. *Curr Opin Genet Dev*. 2014; 24: 30-7.
56. Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, *et al*. Cancer. TERT pro moter mutations and telomerase reactivation in urothelial cancer. *Science*. 2015; 347: 1006-10.
57. Armanios M, Blackburn EH. The telomere syndromes. *Nat Rev Genet*. 2012; 13: 693-704.
58. Campisi J, di Fagagna F. Cellular senescence: when bad things happen to good cells. *Nat Rev Mol Cell Biol*. 2007; 8: 729-40.
59. Collado M, Bisco MA, Serrano M. Cellular senescence in cancer and aging. *Cell*. 2007; 130: 223-33.
60. Hayflick L, Moorehead PS. The serial cultivation of human diploid cell strains. *Exp. Cell Res*. 1961; 25: 585-621.
61. Hayflick L. The illusion of cell immortality. *Br J Cancer*. 2000; 83: 841-6.
62. Boukamp P. Biological clocks in the ageing cell. In: Von Zglinicki T, editor. *Ageing at the Molecular Level*. Dordrecht; Kluwer Academic: 2003.
63. Blackburn EH. Telomere states and cell fates. *Nature*. 2000; 408: 53-6.
64. Von Zglinicki T, Saretzki G, Ladhoff J, di Fagagna Fd, Jackson SP. Human cell senescence as a DNA damage response. *Mech Ageing Dev*. 2005; 126: 111-7.
65. Burton DGA. Cellular senescence, ageing and disease. *Age*. 2009; 31: 1-9.
66. Joosten SA, van Ham V, Nolan CE, Borrias MC, Jardine AG, Shiels PG, *et al*. Telomere shortening and cellular senescence in a model of chronic renal allograft rejection. *Am J Pathol*. 2003; 162: 1305-12.
67. von Zglinicki T, Pilger R, Sitt N. Accumulation of single-strand breaks is the major cause of telomere shortening in human fibroblasts. *Free Radic Biol Med*. 2000; 28: 64-74.
68. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, *et al*. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. *Nature*. 2006; 444: 638-42.
69. von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and age-related diseases. *Curr Mol Med*. 2005; 5: 197-203.
70. Burton DG, Allen MC, Bird JL, Faragher RG. Bridging the gap: ageing, pharmacokinetics and pharmacodynamics. *J Pharm Pharmacol*. 2005; 57: 671-9.
71. Burton DG, Sheerin A, Ostler EL, Smith K, Giles PJ, Lowe J, *et al*. Cyclin D1 over-expression permits the reproducible detection of senescent human vascular smooth muscle cells. *Ann NY Acad Sci*. 2007; 1119: 20-31.
72. Campisi J. Aging and cancer: the double-edged sword of replicative senescence. *J Am Geriatr Soc*. 1997; 45: 482-8.
73. Campisi J. The biology of replicative senescence. *Eur J Cancer*. 1997; 33: 703-9.
74. Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. *Nat Rev Mol Cell Biol*. 2006; 7: 667-77.
75. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. *Cell*. 2006; 127: 265-75.
76. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell*. 1997; 88: 593-602.
77. Hahn WC, Weinberg RA. Rules for making human tumor cells. *N Engl J Med*. 2008; 347: 1593-603.
78. Blagosklonny MV. Cell cycle arrest is not senescence. *Aging*. 2011; 3: 94-101.
79. Acosta JC, O'Loughlin A, Banito A, Guijarro MV, Augert A, Raguz S, *et al*. Chemokine signaling via the CXCR2 receptor reinforces senescence. *Cell*. 2008; 133: 1006-18.
80. Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. *Cancer Res*. 2006; 66: 794-802.
81. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz D, Goldstein J, *et al*. Senescence-associated secretory phenotypes reveal cell

- non-autonomous functions of oncogenic RAS and the p53 tumor suppressor. *PLoS Biol.* 2008; 6: 2853-68.
82. Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. *Nature Cell Biol.* 2006; 8: 877-84.
 83. Kuilman T, Michaloglou C, Vredeveld LCW, Douma S, van Doorn R, Desmet CJ, *et al.* Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. *Cell.* 2008; 133: 1019-31.
 84. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. *Cell.* 2008; 132: 363-74.
 85. Campisi J, Andersen J, Kapahi P, Melov S. Cellular senescence: a link between cancer and age-related degenerative disease? *Semin Cancer Biol.* 2011; 21: 354-9.
 86. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, *et al.* 1995. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. *Proc Natl Acad Sci* 92: 9363-7. 87. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated β -galactosidase (SA- β -gal) activity, a biomarker of senescent cells in culture and in vivo. *Nat Protoc.* 2009; 4: 1798-806.
 88. Lee BY, Han JA, Im JS, Morrone A, Johung K, Goodwin EC, *et al.* Senescence-associated β -galactosidase is lysosomal β -galactosidase. *Aging Cell.* 2006; 5: 187-95.
 89. Kurz DJ, Decary S, Hong Y, Erusalimsky JD. Senescence-associated β -galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. *J Cell Sci.* 2000; 113: 3613-622.
 90. Yang NC, Hu ML. The limitations and validities of senescence associated- β -galactosidase activity as an aging marker for human foreskin fibroblast Hs68 cells. *Exp Gerontol.* 2005; 40: 813-9.
 91. Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. *Genes Dev* 2016; 24: 2463-79.
 92. Kirkwood TB, Holliday R. The evolution of ageing and longevity. *Proc R Soc Lond B Biol Sci.* 1979; 205: 531-46.
 93. Kanapuru B, Ershler WB. Inflammation, coagulation, and the pathway to frailty. *Am J Med.* 2009; 122: 605-13.
 94. Finkel T, Serrano M, Blasco MA. The common biology of cancer and ageing. *Nature.* 2007; 448: 767-74.
 95. Kirkwood T.B. Understanding the odd science of aging. *Cell.* 2005; 120: 437-47. <https://doi.org/10.1016/j.cell.2005.01.027>
 96. Sahin E, DePinho R. Linking functional decline of telomeres, mitochondria and stem cells during ageing. *Nature.* 2010; 464: 520-8.
 97. Aubert G, Lansdorp PM. Telomeres and aging. *Physiol Rev.* 2008; 88: 557-79.
 98. Sharpless NE, DePinho RA. How stem cells age and why this makes us grow old. *Nature Rev Mol Cell Biol.* 2007; 8: 703-13.
 99. Rossi D J, Jamieson CH, Weissman IL. Stems cells and the pathways to aging and cancer. *Cell.* 2008; 132: 681-96.
 100. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T, *et al.* Modulation of mammalian life span by the short isoform of p53. *Genes Dev.* 2004; 18: 306-19.
 101. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, *et al.* p53 mutant mice that display early ageing-associated phenotypes. *Nature.* 2002; 415: 45-53.
 102. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. *Nature.* 2009; 460: 587-91.
 103. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, *et al.* Extension of life-span by introduction of telomerase into normal human cells. *Science.* 1998; 279: 349-52.
 104. Shay JW, Wright WE, Werbin H. Defining the molecular mechanism of human cell immortalization. *Biochim Biophys Acta.* 1991; 1072: 1-7. doi: 10.1016/0304-419x(91)90003-4.
 105. Verfaillie CM, Pera MF, Lansdorp PM. Stem cells: hype and reality. *Hematology.* 2002; (n.v): 369-91.
 106. De Lange T. Telomere dynamics and genome instability in human cancer. In: Blackburn EH, Greider CW, editors. *Telomeres. Plainview: Cold Spring Harbor Laboratory; 1995.* p.265-93.
 107. Sharpless NE, DePinho RA. Telomeres, stem cells, senescence, cancer. *J Clin Invest.* 2004; 113: 160-8.
 108. Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L, *et al.* Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. *Nature.* 2000; 406: 641-5.
 109. Vousden KH, Lane DP. p53 in health and disease. *Nat Rev Mol Cell Biol.* 2007; 8: 275-83.
 110. Maciejowski J, de Lange T. Telomeres in cancer: tumour suppression and genome instability. *Nat Rev Mol Cell Biol.* 2017; 18: 175-86.
 111. Langford LA, Piatyszek MA, Xu RS, Schold SC, Wright WE, Shay JW. Telomerase activity in ordinary meningiomas predicts poor outcome. *Human Pathol.* 1997; 28: 416-20.
 112. Roger L, Jones RE, Heppel NH, Williams GT, Sampson JR, Baird DM, *et al.* Extensive telomere erosion in the initiation of colorectal adenomas and its association with chromosomal instability. *J Natl Cancer Inst.* 2013; 105: 1202-11.
 113. Riboni R, Casati A, Nardo T, Zaccaro E, Ferretti L, Nuzzo F, *et al.* Telomeric fusions in cultured human fibroblasts as a source of genomic instability. *Cancer Genet Cytogenet.* 1997; 95: 130-6.
 114. Maciejowski J, Li Y, Bosco N, Campbell PJ, de Lange T. Chromothripsis and kataegis induced by telomere crisis. *Cell.* 2015; 163: 1641-54.
 115. Davoli T, Denchi EL, de Lange T. Persistent telomere damage induces bypass of mitosis and tetraploidy. *Cell.* 2010; 141: 81-93.
 116. Davoli T, de Lange T. Telomere-driven tetraploidization occurs in human cells undergoing crisis and promotes transformation of mouse cells. *Cancer Cell.* 2012; 21: 765-76.
 117. Llorente B, Smith CE, Symington LS. Break-induced replication: what is it and what is it for? *Cell Cycle.* 2008; 7: 859-64.
 118. Anand RP, Lovett ST, Haber JE. Break-induced DNA replication. *Cold Spring Harb Perspect Biol.* 2013; 5: a010397. doi: 10.1101/cshperspect.a010397.
 119. Shih IM, Zhou W, Goodman SN, Lengauer C, Kinzler KW, Vogelstein B. Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. *Cancer Res.* 2001; 61: 818-22.
 120. Liddiard K, Ruis B, Takasugi T, Harvey A, Ashelford KE, Hendrickson EA, *et al.* Sister chromatid telomere fusions, but not NHEJ-mediated inter-chromosomal telomere fusions, occur independently of DNA ligases 3 and 4. *Genome Res.* 2016; 26: 588-600.
 121. Shay JW, Bacchetti S. A survey of telomerase in human cancer. *Eur J Cancer.* 1997; 33: 787-91.
 122. Shay JW. Role of Telomeres and Telomerase in Aging and Cancer. *Cancer Discov.* 2016; 6: 584-93.
 123. Harley CB. Telomerase and cancer therapeutics. *Nat Rev Cancer.* 2008; 8: 167-79.
 124. Hiyama E, Hiyama K. Telomerase as tumor marker. *Cancer Lett.* 2003; 194: 221-33.
 125. Phatak P, Burger AM. Telomerase and its potential for therapeutic intervention. *Br J Pharmacol.* 2007; 152: 1003-11.
 126. Armanios M, Greider CW. Telomerase and cancer stem cells. *Cold Spring Harb Symp Quant Biol.* 2005; 70: 205-8. h
 127. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. *Cancer Res.* 2007; 67: 4827-33.

128. Phatak P, Cookson JC, Dai F, Smith V, Gartenhaus RB, Stevens MF, *et al.* Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. *Br J Cancer.* 2007; 96: 1223-33.
129. Tchkonja T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. *J Clin Invest.* 2013; 123: 966-72.
130. Suram A, Kaplunov J, Patel PL, Ruan H, Cerutti A, Boccardi V, *et al.* Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions. *EMBO J.* 2012; 31: 2839-51.
131. Chen JH, Stoeber K, Kingsbury S, Ozanne SE, Williams GH, Hales CN. Loss of proliferative capacity and induction of senescence in oxidatively stressed human fibroblasts. *J Biol Chem.* 2004; 279: 49439-46.
132. Courtois-Cox S, Jones SL, Cichowski K. Many roads lead to oncogene-induced senescence. *Oncogene.* 2008; 27: 2801-9.
133. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AHFM, Schlegelberger B, *et al.* Oncogene-induced senescence as an initial barrier in lymphoma development. *Nature.* 2005; 436: 660-5.
134. Haigis KM, Sweet-Cordero A. New insights into oncogenic stress. *Nat Genet.* 2011; 43: 177-8.
135. Braig M, Schmitt CA. Oncogene-induced senescence: putting the brakes on tumor development. *Cancer Res.* 2006; 66: 2881-4.
136. Prieur A, Peepers DS. Cellular senescence in vivo: a barrier to tumorigenesis. *Curr Opin Cell Biol.* 2008; 20: 150-5.
137. Campisi J. Cellular senescence as a tumor-suppressor mechanism. *Trends Cell Biol.* 2001; 11: S27-31.
138. Guerra C, Collado M, Navas C, Schuhmacher AJ, Hernández-Porras I, Cañamero M, *et al.* Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. *Cancer Cell.* 2011; 19: 728-39.
139. Burton DG. Cellular senescence, ageing and disease. *Age.* 2009; 31: 1-9. doi: 10.1007/s11357-008-9075-y.
140. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. *Cell.* 2005; 120: 513-22.
141. Jayapalan JC, Sedivy JM. Cellular senescence and organismal aging. *Mech Ageing Dev.* 2008; 129: 467-74.
142. Baker DJ, Perez-Terzic C, Jin F, Pitel KS, Niederländer NJ, Jeganathan K, *et al.* Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. *Nat Cell Biol.* 2008; 10: 825-36.
143. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, *et al.* Ink4a/Arf expression is a biomarker of aging. *J Clin Invest.* 2004; 114: 1299-307.
144. Jayapalan JC, Ferreira M, Sedivy JM, Herbig U. Accumulation of senescent cells in mitotic tissue of aging primates. *Mech Ageing Dev.* 2007; 128: 36-44.
145. Waaijer ME, Parish WE, Strongtharm BH, van Heemst D, Slagboom PE, de Craen AJ, *et al.* The number of p16INK4a positive cells in human skin reflects biological age. *Ageing Cell.* 2012; 11: 722-5.
146. Baker DJ, Wijshake T, Tchkonja T, LeBrasseur NK, Childs BG, van de Sluis B, *et al.* Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. *Nature.* 2011; 479: 232-6.
147. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. *JAMA.* 1979; 241: 2035-8.
148. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardio-vascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. *Lancet.* 2006; 368: 29-36.
149. D'Mello MJJ, Ross SA, Briel M, Anand SS, Gerstein H, Pare G. Association between shortened leukocyte telomere length and cardiometabolic outcomes: Systematic Review and Meta-Analysis. *Circ Cardiovasc Genet.* 2015; 8: 82-90.
150. Muezzinler A, Zaineddin AK, Brenner H. A systematic review of leukocyte telomere length and age in adults. *Ageing Res Rev.* 2013; 12: 509-19.
151. Cherkas LF, Hunkin JL, Kato BS, Richards JB, Gardner JP, Surdulescu GL, *et al.* The association between physical activity in leisure time and leukocyte telomere length. *Arch Intern Med.* 2008; 168: 154-8.
152. Song Z, von Figura G, Liu Y, Kraus JM, Torrice C, Dillon P, *et al.* Lifestyle impacts on the aging-associated expression of biomarkers of DNA damage and telomere dysfunction in human blood. *Ageing cell.* 2010; 9: 607-15.
153. Njajou OT, Cawthon RM, Blackburn EH, Harris TB, Li R, Sanders JL, *et al.* Shorter telomeres are associated with obesity and weight gain in the elderly. *Int J Obes (Lond).* 2012; 36: 1176-9.
154. Tzanetakou IP, Katsilambros NL, Benetos A, Mikhailidis DP, Perrea DN, *et al.* "Is obesity linked to aging?": adipose tissue and the role of telomeres. *Ageing Res Rev.* 2012; 11: 220-9.
155. Kong CM, Lee XW, Wang X. Telomere shortening in human diseases. *FEBS J.* 2013; 280: 3180-93.
156. Eitan E, Hutchison ER, Mattson MP. Telomere shortening in neurological disorders: an abundance of unanswered questions. *Trends Neurosci.* 2014; 37: 256-63.
157. von Zglinicki T. Oxidative stress shortens telomeres. *Trends Biochem Sci.* 2002; 27: 339-44.
158. Uziel Y, Chapnick G, Rothschild M, Tauber T, Press J, Harel L, *et al.* Nitrous oxide sedation for intra-articular injection in juvenile idiopathic arthritis. *Pediatr Rheumatol Online J.* 2008; 6: 1. doi: 10.1186/1546-0096-6-1.
159. Pedersen-Lane JH, Zurier RB, Lawrence DA. Analysis of the thiol status of peripheral blood leukocytes in rheumatoid arthritis patients. *J Leukoc Biol.* 2007; 81: 934-41.
160. Sampson MJ, Winterbone MS, Hughes JC, Dozio N, Hughes DA. Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes. *Diabetes Care.* 2006; 29: 283-9.
161. Fumagalli M, Rossiello F, Clerici M, Barozzi S, Cittaro D, Kaplunov JM, *et al.* Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. *Nat Cell Biol.* 2012; 14: 355-65.
162. Morocz M, Kálmán J, Juhász A, Sinkó I, McGlynn AP, Downes CS, *et al.* Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer's disease. *Neurobiol Aging.* 2002; 23: 47-53.
163. Jaworska A, Dzбек J, Styczynska M, Kuznicki J. Analysis of calcium homeostasis in fresh lymphocytes from patients with sporadic Alzheimer's disease or mild cognitive impairment. *Biochim Biophys Acta.* 2013; 1833: 1692-9.
164. Liu JP, Chen SM, Cong YS, Nicholls C, Zhou SF, Tao ZZ, *et al.* Regulation of telomerase activity by apparently opposing elements. *Ageing Res Rev.* 2010; 9: 245-56.
165. Bauer ME, Jeckel CM, Luz C. The role of stress factors during aging of the immune system. *Ann N Y Acad Sci.* 2009; 1153: 139-52.
166. Epel ES. Psychological and metabolic stress: a recipe for accelerated cellular aging? *Hormones (Athens).* 2009; 8: 7-22.
167. Price LH, Kao HT, Burgers DE, Carpenter LL, Tyrka AR. Telomeres and early-life stress: an overview. *Biol Psychiatry.* 2013; 73: 15-23.
168. Weng NP. Telomeres and immune competency. *Curr Opin Immunol.* 2012; 24: 47-5.
169. Rolyan H, Scheffold A, Heinrich A, Begus-Nahrmann Y, Langkopf BH, Hölter SM, *et al.* Telomere shortening reduces Alzheimer's disease amyloid pathology in mice. *Brain.* 2011; 134: 2044-56.

170. Schwartz M, Shechter R. Systemic inflammatory cells fight off neurodegenerative disease. *Nat Rev Neurol.* 2010; 6: 405-10.
171. Jurk D, Wang C, Miwa S, Maddick M, Korolchuk V, Tzolou A, *et al.* Postmitotic neurons develop a p21-dependent senescence-like phenotype driven by a DNA damage response. *Aging Cell.* 2012; 11: 996-1004.
172. Hemann MT, Strong MA, Hao LY, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. *Cell.* 2001; 107: 67-77.
173. Vera E, Bernardes de Jesus B, Foronda M, Flores JM, Blasco MA. The rate of increase of short telomeres predicts longevity in mammals. *Cell Rep.* 2012; 2: 732-7.
174. Shalev I, Moffitt TE, Sugden K, Williams B, Houts RM, Danese A, *et al.* Exposure to violence during childhood is associated with telomere erosion from 5 to 10 years of age: a longitudinal study. *Mol Psychiatry.* 2013; 18: 576-81.
175. Kiecolt-Glaser JK, Gouin JPP, Weng NPP, Malarkey WB, Beversdorf DQ, Glaser R. Childhood adversity heightens the impact of later-life caregiving stress on telomere length and inflammation. *Psychosom Med* 2011; 73: 16-22.
176. Drury SS, Theall K, Gleason MM, Smyke AT, De Vivo I, Wong JY, *et al.* Telomere length and early severe social deprivation: linking early adversity and cellular aging. *Mol Psychiatry.* 2012; 17: 719-27.
177. Entringer S, Epel ES, Kumsta R, Lin J, Hellhammer DH, Blackburn EH, *et al.* Stress exposure in intrauterine life is associated with shorter telomere length in young adulthood. *Proc Natl Acad Sci USA.* 2011; 108: E513-8.
178. Glass D, Parts L, Knowles D, Aviv A, Spector TD. No correlation between childhood maltreatment and telomere length. *Biol Psychiatry.* 2010; 68: e21-2.
179. Damjanovic AK1, Yang Y, Glaser R, Kiecolt-Glaser JK, Nguyen H, Laskowski B, *et al.* Accelerated telomere erosion is associated with a declining immune function of caregivers of Alzheimer's disease patients. *J Immunol.* 2007; 179: 4249-54.
180. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, *et al.* Accelerated telomere shortening in response to life stress. *Proc Natl Acad Sci USA.* 2004; 101: 17312-5.
181. O'Donovan A, Tomiyama AJ, Lin J, Puterman E, Adler NE, Kemeny M, *et al.* Stress appraisals and cellular aging: a key role for anticipatory threat in the relationship between psychological stress and telomere length. *Brain Behav Immun.* 2012; 26: 573-9.
182. Puterman E, Lin J, Blackburn E, O'Donovan A, Adler N, Epel E. The power of exercise: buffering the effect of chronic stress on telomere length. *PLoS One.* 2010; 5: e10837. doi: 10.1371/journal.pone.0010837.
183. Humphreys J, Epel ES, Cooper BA, Lin J, Blackburn EH, Lee KA. Telomere shortening in formerly abused and never abused women. *Biol Res Nurs.* 2012; 14: 115-23.
184. Hoen PW, de Jonge P, Na BY, Farzaneh-Far R, Epel E, Lin J, *et al.* Depression and leukocyte telomere length in patients with coronary heart disease: data from the Heart and Soul Study. *Psychosom Med.* 2011; 73: 541-7.
185. Verhoeven JE, Révész D, Epel ES, Lin J, Wolkowitz OM, Penninx BW. Major depressive disorder and accelerated cellular aging: results from a large psychiatric cohort study. *Mol Psychiatry.* 2014; 19: 895-901.
186. Wolkowitz OM, Mellon SH, Epel ES, Lin J, Dhabhar FS, Su Y, *et al.* Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress--preliminary findings. *PLoS One.* 2011; 6: e17837.
187. Puterman E, Lin J, Krauss J, Blackburn EH, Epel ES. Determinants of telomere attrition over 1 year in healthy older women: stress and health behaviors matter. *Mol Psychiatry.* 2015; 20: 529-35.
188. Holohan B, Wright WE, Shay JW. Cell biology of disease: Telomeropathies: an emerging spectrum disorder. *J Cell Biol.* 2014; 205: 289-99.
189. Kirwan M, Dokal I. Dyskeratosis congenita: a genetic disorder of many faces. *Clin Genet.* 2008; 73: 103-12.
190. Heiss NS, Knight SW, Vulliamy TJ, Klauck SM, Wiemann S, Mason PJ, *et al.* X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. *Nat Genet.* 1998; 19: 32-8.
191. Tsangaris E, Adams SL, Yoon G, Chitayat D, Lansdorp P, Dokal I. Ataxia and pancytopenia caused by a mutation in TINF2. *Hum Genet.* 2008; 124: 507-13.
192. Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. *Nature.* 1999; 402: 551-5.
193. Dokal I. Dyskeratosis congenita. *Hematology Am Soc Hematol Educ Program.* 2011; 2011: 480-6.
194. Young NS. Bone marrow failure and the new telomere diseases: practice and research. *Hematology.* 2012; 17 (Suppl 1): S18-21.
195. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, *et al.* Telomerase mutations in families with idiopathic pulmonary fibrosis. *N Engl J Med.* 2007. 356: 1317-26.
196. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, *et al.* Adult-onset pulmonary fibrosis caused by mutations in telomerase. *Proc Natl Acad Sci USA.* 2007; 104: 7552-7.
197. Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL, *et al.* Telomere shortening in familial and sporadic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2008; 178: 729-37.
198. Calado RT, Regal JA, Kleiner DE, Schrupp DS, Peterson NR, Pons V, *et al.* A spectrum of severe familial liver disorders associate with telomerase mutations. *PLoS ONE.* 2009; 4: e7926. doi: 10.1371/journal.pone.0007926.
199. Fogarty PF, Yamaguchi H, Wiestner A, Baerlocher GM, Sloand E, Zeng WS, *et al.* Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. *Lancet.* 2003; 362: 1628-30.
200. Calado RT, Regal JA, Hills M, Yewdell WT, Dalmazzo LF, Zago MA, *et al.* Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. *Proc Natl Acad Sci USA.* 2009; 106: 1187-92.
201. Ludwig FC, Smoke ME. The measurement of biological age. *Exp Aging Res.* 1980; 6: 497-522.
202. Schneider EL, Reff ME. Biological Markers of Aging. Bethesda: U.S. Dept. of Health and Human Services, National Institutes of Health, Public Health Service; 1982.
203. Sprott RL, Schneider EL. Biomarkers of aging. In: Hart S, Editor. *Proceedings of the International Conference on Nutrition and Aging.* New York: A.R. Liss; 1985. p.43-52.
204. Sprott RL. Biomarkers of aging and disease: Introduction and definitions. *Exp Gerontol.* 2010; 45: 2-4.
205. Butler RN, Sprott R, Warner H, Bland J, Feuers R, Forster M, *et al.* Biomarkers of aging: from primitive organisms to humans. *J Gerontol A Biol Sci Med Sci.* 2004; 59: B560-7.
206. Blasco MA. Telomeres and human disease: Ageing, cancer and beyond. *Nat Rev Genet.* 2005; 6: 611-22.
207. Jaskelioff M, Muller FL, Paik JH, Thomas E, Jiang S, Adams AC, *et al.* Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. *Nature.* 2011; 469: 102-6.
208. Rudolph KL, Chang S, Millard M, Schreiber-Agus N, DePinho RA. Inhibition of experimental liver cirrhosis in mice by telomerase

- gene delivery. *Science*. 2000; 287: 1253-8.
209. Honig LS, Schupf N, Lee JH, Tang MX, Mayeux R. Shorter telomeres are associated with mortality in those with APOE epsilon4 and dementia. *Ann Neurol*. 2006; 60: 181-7.
 210. Fauce SR, Jamieson BD, Chin AC, Mitsuyasu RT, Parish ST, Ng HL, *et al*. Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes. *J Immunol*. 2008; 181: 7400-6.
 211. Harley CB, Liu W, Blasco M, Vera E, Andrews WH, Briggs LA, Raffaele JM. A natural product telomerase activator as part of a health maintenance program. *Rejuvenation Res*. 2011; 14: 45-56.
 212. Dagarag M, Evazyan T, Rao N, Effros RB. Genetic manipulation of telomerase in HIV-specific CD8+ T cells: Enhanced antiviral functions accompany the increased proliferative potential and telomere length stabilization. *J Immunol*. 2004; 173: 6303-11.
 213. Itahana K, Campisi J, Dimri GP. Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. *Methods Mol Biol*. 2007; 371: 21-31.
 214. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, *et al*. Tumour biology: Senescence in premalignant tumours. *Nature*. 2005; 436: 642.
 215. Cao L, Li W, Kim S, Brodie SG, Deng CX. Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Bcr1 full-length isoform. *Genes Dev*. 2003; 17: 201-13.
 216. Sun LQ, Lee DW, Zhang Q, Xiao W, Raabe EH, Meeker A, *et al*. Growth retardation and premature aging phenotypes in mice with disruption of the SNF2-like gene, PASG. *Genes Dev*. 2004; 18: 1035-46.
 217. Castro P, Giri D, Lamb D, Ittmann M. Cellular senescence in the pathogenesis of benign prostatic hyperplasia. *Prostate*. 2003; 55: 30-8.
 218. Mishima K, Handa JT, Aotaki-Keen A, Luty GA, Morse LS, Hjelmeland LM. Senescence-associated beta-galactosidase histochemistry for the primate eye. *Invest Ophthalmol Vis Sci*. 1999; 40: 1590-3.
 219. Melk A, Schmidt BM, Takeuchi O, Sawitzki B, Rayner DC, Halloran PF. Expression of p16INK4a and other cell cycle regulator and senescence associated genes in aging human kidney. *Kidney Int*. 2004; 65: 510-20.
 220. Collado M, Serrano M. Senescence in tumours: Evidence from mice and humans. *Nat Rev Cancer*. 2010; 10: 51-7.
 221. Narita M, Nunez S, Heard E, Narita M, Lin AW, Hearn SA, *et al*. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. *Cell*. 2003; 113: 703-16.
 222. Zhang R, Chen W, Adams PD. Molecular dissection of formation of senescence-associated heterochromatin foci. *Mol Cell Biol*. 2007; 27: 2343-58.
 223. Funayama R, Ishikawa F. Cellular senescence and chromatin structure. *Chromosoma*. 2007; 116: 431-40.
 224. Bernardes de Jesus B, Blasco MA. Assessing cell and organ senescence biomarkers. *Circ Res*. 2012; 111: 97-109.
 225. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. *Curr Biol*. 2003; 13: 1549-56.
 226. Zhu H, Belcher M, van der Harst P. Healthy aging and disease: Role for telomere biology? *Clin Sci (Lond)*. 2011; 120: 427-40.
 227. Sarin KY, Cheung P, Gilson D, Lee E, Tennen RI, Wang E, *et al*. Conditional telomerase induction causes proliferation of hair follicle stem cells. *Nature*. 2005; 436: 1048-52.
 228. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, *et al*. Telomerase modulates Wnt signalling by association with target gene chromatin. *Nature*. 2009; 460: 66-72.
 229. Rao TP, Kühl M. An updated overview on Wnt signaling pathways: A prelude for more. *Circ Res*. 2010; 106: 1798-806.
 230. Jager K, Walter M. Therapeutic targeting of telomerase. *Genes (Basel)*. 2016; 7: E39. doi: 10.3390/genes7070039.
 231. Dock JN, Effros RB. Role of CD8 T cell replicative senescence in human aging and in HIV-mediated immunosenescence. *Aging Dis*. 2011; 2: 382-97.
 232. Harley CB, Liu W, Blasco M, Vera E, Andrews WH, Briggs LA, *et al*. A natural product telomerase activator as part of a health maintenance program. *Rejuvenation Res*. 2011; 14: 45-56.
 233. Bernardes de Jesus B, Schneeberger K, Vera E, Tejera A, Harley CB, Blasco MA. The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence. *Aging Cell*. 2011; 10: 604-21.
 234. Pearce VP, Sherrell J, Lou Z, Kopelovich L, Wright WE, Shay JW. immortalization of epithelial progenitor cells mediated by resveratrol. *Oncogene*. 2008; 27: 2365-74.
 235. Xia L, Wang XX, Hu XS, Guo XG, Shang YP, Chen HJ, *et al*. Resveratrol reduces endothelial progenitor cells senescence through augmentation of telomerase activity by Akt-dependent mechanisms. *Br J Pharmacol*. 2008; 155: 387-94.
 236. Sprouse AA, Steding CE, Herbert BS. Pharmaceutical regulation of telomerase and its clinical potential. *J Cell Mol Med*. 2012; 16: 1-7. doi: 10.1111/j.1582-4934.2011.01460.x.
 237. Babizhayev MA, Yegorov YE. Telomere attrition in lens epithelial cells - a target for N-acetylcarnosine therapy. *Front Biosci (Landmark Ed)*. 2010; 15: 934-56.
 238. Eitan E, Tichon A, Gazit A, Gitler D, Slavin S, Priel E. Novel telomerase-increasing compound in mouse brain delays the onset of amyotrophic lateral sclerosis. *EMBO Mol Med*. 2012; 4: 313-29.
 239. Haendeler J, Hoffmann J, Diehl JF, Vasa M, Spyridopoulos I, Zeiher AM, *et al*. Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells. *Circ Res*. 2004; 94: 768-75.
 240. Tanaka Y, Moritoh Y, Miwa N. Age-dependent telomere-shortening is repressed by phosphorylated alpha-tocopherol together with cellular longevity and intracellular oxidative-stress reduction in human brain microvascular endothelial cells. *J Cell Biochem*. 2007; 102: 689-703.
 241. Passos JF, Saretzki G, Ahmed S, Nelson G, Richter T, Peters H, *et al*. Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. *PLoS Biol*. 2007; 5: e110. doi: 10.1371/journal.pbio.0050110.
 242. Brouillette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, *et al*. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: A nested case-control study. *Lancet*. 2007; 369: 107-14.
 243. Spyridopoulos I, Haendeler J, Urbich C, Brummendorf TH, Oh H, Schneider MD, Zeiher AM, *et al*. Statins enhance migratory capacity by upregulation of the telomere repeat binding factor TRF2 in endothelial progenitor cells. *Circulation*. 2004; 110: 3136-42.
 244. Dong XX, Hui YJ, Xiang WX, Rong ZF, Jian S, Zhu CJ. Ginkgo Biloba extract reduces endothelial progenitor-cell senescence through augmentation of telomerase activity. *J Cardiovasc Pharmacol*. 2007; 49: 111-5.
 245. Bar C, Thum T. Changing Direction: From Therapeutic Telomerase Inhibition to Activation? *Circ Res*. 2017; 120: 1393-5.
 246. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumor cells with defined genetic elements. *Nature*. 1999; 400: 464-8.